HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us



Chicago-based Investor Awareness, Inc., a full service Strategic Management Consulting firm for private and publicly traded companies with customized programs to generate awareness among members of the international financial community.

Since our founding in 1994, Investor Awareness has strategically worked with hundreds of companies in a wide variety of industries. Our hands-on approach helps our clients realize that investors don’t come just from Wall Street, but can be found all over the world. By making relationship building a priority, we have compiled a proprietary database of 69,000 financial industry contacts.

Our staff is not afraid to roll up its sleeves and work hard on behalf of our clients. In fact, many of our colleagues and partners notice that Investor Awareness brings an unprecedented amount of dedication and energy to the tasks at hand, a commitment that impacts both the quality of our relationships and level of results that we deliver.

Investor Awareness recognizes that media and investor relations are intricately connected, and employs a staff with expertise in both areas that work congruently on the entire package. This focus enables us to maintain a consistent message and public image to all audiences.


read more

Company Profiles

Upcoming Events

There are no events to display at this time.
Complete Events List

Tony Schor Entrepreneur


Chicago Now


News and Updates

Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
LOS ANGELES, CA--(Aug 15, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017. (full story)

More Articles



  Disclaimer     Financial Glossary

©2015 Investor Awareness, Inc. All rights reserved